dehydration, confusion, incontinence, and diabetes complications, such as neuropathy or nephropathy. Typically, the disease is asymptomatic and usually diagnosed based on routinely performed laboratory studies (Box 1).
13,15
The criteria for diagnosis are the same for younger and older adults. 13 TheyarebasedonplasmaglucoseandhemoglobinA 1c (HbA 1c ) thresholds that increase the risk of developing retinopathy. 15 Incident diabetes among older compared with younger adults more often manifests as postprandial rather than fasting hyperglycemia.
16
Measurement of HbA 1c is often more convenient than obtaining a fasting plasma glucose, but there are some clinical conditions common in older persons, such as chronic kidney disease or anemia, that may restrict the ability of HbA 1c to accurately reflect average glycemia.
14 In adults older than 70 years, the nonfatal diabetes complications with the highest incidence rates include congestive heart failure, coronary artery disease, and cerebrovascular disease. 17 How-plications and the risk of therapy resulting in hypoglycemia become critically important to consider when setting therapeutic goals. The goals of treatment of type 2 diabetes are to improve symptoms (if present), reduce the risk of acute and chronic diabetes complications, and minimize harms and burdens of therapy. Glycemic control has been the central focus of diabetes care for decades [18] [19] [20] [21] [22] [23] and is the primary subject of this review. Randomized trials have shown that intensive glycemic control may lower the risk of some long-term complications (ie, microvascular disease 18, 19 ) but increase the risk of harm (ie, hypoglycemia [18] [19] [20] [21] [22] [23] ). Decisions about glycemic treatment involve trade-offs between these possible benefits versus the potential harms and burdens of treatment. For some persons, the benefits of tight glycemic control may outweigh the harms. For others, the harms may be more important than the benefits. Recent guidelines on glucose-lowering treatment of older adults acknowledge that the likelihood of benefits and harms varies across patient subgroups and endorse individualized glycemic targets.
13,24-28 However, there is substantial uncertainty about how to individualize glycemic targets and treatment plans for older adults with multiple comorbidities and risk factors. The goal of this article is to synthesize the available evidence and provide clinicians practical information to guide discussions about glycemic treatment with these vulnerable patients.
Methods
We used the Cochrane review of randomized clinical trials (RCTs) for intensive glycemic control to identify studies from inception of the included databases through 2012. Using the same search strategy as the Cochrane review, we searched MEDLINE to identify additional studies published between January 2013 and June 2015. We included randomized, double-blind trials with more than 100 participants in each group with type 2 diabetes, with at least 2 years of follow-up after randomization, with prespecified cardiovascular and microvascular outcomes, and with follow-up of 90% or more of randomized participants for vital status ( eTable 1 in the Supplement). We also determined how many of these trials included patients aged 80 years or older. We used the American College of Cardiology/American Heart Association (ACC/AHA) methods 29 to assess the strength of the evidence on the benefits and harms of glucose-lowering treatment based on the obtained data. The goal was to provide information that would help an older patient better understand what to expect from glucose-lowering treatment,whatthebenefitsandharmsare,andinwhattimeframebenefits and harms are most likely. Moreover, in order to make an informed decision, the patient needs to understand the strength of the evidence.
Results

Glucose-Lowering Treatment in Older Adults-Deficiencies of the Evidence Base
The evidence about the benefits and harms of intensive vs standard glycemic control comes primarily from 4 large RCTs: UK Prospective (Table 1) . These landmark trials allocated glucoselowering treatments in a randomized and concealed fashion and maintained balance across the 2 groups throughout follow-up, resulting in a relatively low risk of bias. 36 The definitions of the outcomes in these trials are summarized in Box 2. However, applying these data to questions of benefits and harms for older patients presents several challenges.
Trials Have Focused on Younger Patients
The mean age of participants in the major RCTs ranged between 53 and 66 years, and very few (if any) adults older than 80 years were included (Table 1) . 37, 38 One important reason for this underrepresentation is that intensive glycemic control in older patients raised safety concerns. Early on in the ACCORD trial, the data and safety monitoring board specifically recommended against further recruitment of participants older than 80 years because of frequent hypoglycemia observed in this group. 39 Therefore, applying the results of the major RCTs to older adults is problematic.
Trials Have Focused on Surrogate End Points Rather Than Clinical Outcomes
Clinical trials of glucose-lowering therapies often rely on intermediate or surrogate end points, such as albuminuria or worsening creatinine (Table 1) . Although these end points are strongly associated with clinical outcomes such as dialysis or death due to renal failure, it often takes many years of albuminuria or worsening creatinine to To make informed decisions, patients need individualized information on the relative benefits and risks of glycemic control. However, data about the likelihood of benefits and harms across large subgroups are currently limited. In both the ACCORD and ADVANCE studies, the effect of glycemic control on outcomes did not differ between younger and older ( < 65 vs Ն 65 years) patients. 21, 39 In contrast, other subgroup analyses that explored whether intensive glycemic control is more beneficial in specific patient groups (ie, those with a history of microvascular disease, macrovascular disease, or < 15 years of diabetes) yielded conflicting results. older than 80 years and those with other comorbidities were excluded from the trials, this conclusion may not apply to these patients (level B evidence).
Microvascular Benefits | The ACCORD, ADVANCE, and VADT trials did not show a significant effect of intensive treatment on clinical microvascular outcomes important to patients; however, multiple surrogate end points improved with intensive glycemic control. [20] [21] [22] For example, the ADVANCE trial showed a 14%
(95% CI, 3%-23%) relative risk reduction in the primary microvascular end point, which combined nephropathy and retinopathy composites. This risk reduction was driven by a reduction in nephropathy. In turn, the only component of the nephropathy composite that was significantly reduced was the development of macroalbuminuria (2.9% vs 4.1% in intensive vs standard groups, respectively; P <.001). In the ACCORD and VADT trials, intensive glycemic control did not significantly reduce the secondary microvascular end points that were not based on albuminuria.
20,22,56
In contrast, the UKPDS trial and its follow-up, which reflects medical practice common more than 20 years ago, showed a significant reduction in microvascular complications defined as a composite of photocoagulation, vitreous hemorrhage, and renal failure, ie, based on clinical outcomes important to patients. 51 In the first 8 years of the trial, the control and intensive treatment groups had the same rates of microvascular complications, suggesting no benefits from intensive treatment. In years 8 to 15, the control and intervention group curves diverged, suggesting that the intervention group was starting to benefit based on decreased microvascular complications. Beyond 15 years, the 2 curves did not diverge further, suggesting there was little additional benefit. The absolute benefits were small-microvascular events were reduced from 14.2 to 11.0 per 1000 patient-years. Taken together, the results of these trials suggest that intensive glycemic control does not reduce microvascular outcomes important to patients, at least in the first 8 years of intervention. In contrast, there may be a small microvascular benefit that emerges after 8 to 15 years of treatment, based on the UKPDS trial followup. However, it must be noted that the UKPDS trial results are not readily applicable to older patients with long-standing diabetes because UKPDS trial included younger patients with newly diagnosed disease. In addition, the RCTs used surrogate end points that do not directly apply to clinical outcomes (level B evidence).
Estimate Harms of Intensive Glycemic Control
All 4 major RCTs showed that intensive glycemic control increases the risk of severe hypoglycemia.
18,20-22 Although both younger and older participants are at higher risk of severe hypoglycemia when randomized to intensive glycemic control, 57 the baseline risk of severe hypoglycemia (irrespective of trial group assignment) increases with age (hazard ratio, 1.03 per each 1 year increase, P < .001).
For example, in the ACCORD trial, the annual risk of severe hypoglycemia requiring medical assistance for participants younger than 65 years was 0.8% in the standard glycemic control group vs 2.4% in the intensive glycemic control group. 22 For participants 75 years or older, the annual risk of severe hypoglycemia was much higher: 1.4% in the standard glycemic control group vs 5.3% in the intensive glycemic control group.
58
Other data on harms associated with intensive glycemic control come primarily from epidemiologic analyses. Poor cognitive function has been associated with increased risk of severe hypoglycemia. 59 In addition, age, duration of diabetes, use of multiple medications, frequent hospitalizations, and cognitive impairment (markers of underlying frailty) increase the risk of hypoglycemia.
17,58,60-64 Furthermore, treatment with insulin is associated with the highest risk of hypoglycemia compared with other agents. 63 Taken together, RCTs show that intensive glycemic treatment consistently increases the risk of hypoglycemia by 1.5-to 3-fold. Although the evidence is consistent and based on well-designed RCTs, few older patients were included in these trials. However, results from observational studies support extending these results to older patients (level B evidence).
Establish an Individualized Glycemic Target That Maximizes Benefits but Minimizes Harms According to the Patient's Values
Current evidence suggests that attempts to achieve intensive glycemic control will lead to net harm in the majority of older adults with type 2 diabetes. The ACCORD study showed an increased risk of mortality for patients randomized to intensive glycemic control compared with the standard group. 22 As discussed above, all 4 major trials of intensive glycemic control showed that intensive glycemic treatment increases the rates of severe hypoglycemia compared with standard glycemic control, 20-22 whereas the cardiovascular and microvascular benefits are uncertain for the majority of older adults. Furthermore, modeling studies, based on estimates of microvascular complications drawn from the UKPDS trial (ie, with the most optimistic estimates of benefit), suggest that the marginal benefits of decreasing HbA 1c lower than 7.5% are likely small. 65, 66 Thus, for the vast majority of older patients with diabetes, the harms associated with an HbA 1c target lower than7.5% likely outweigh the benefits. There is wide consensus that HbA 1c values higher than 9% should be avoided because they can lead to immediate symptoms. 25 These symptoms include polyuria, which can occur at blood glucose levels above the renal threshold (>180-200 mg/dL), and may lead to dehydration. In addition, hyperglycemia may lead to fatigue, increased risk for infection, and cognitive impairment. Despite the consensus, there is remarkably little data to support it. Modeling studies suggest that patient preferences are critically important in modulating the target HbA 1c (within the 7.5%-9% range) because they influence the net benefit (or net harm) achieved from more vs less intensive glycemic control. 66 Different patients place different value on avoiding specific burdens (eg, insulin treatment and fingerstick monitoring). 66 An older patient with a life expectancy more than 15 years who perceives little burden from insulin injections may increase his or her chances of an improved quality of life with intensive glycemic control. In contrast, an older patient who expresses a strong desire to avoid burdensome treatments may experience reduced quality of life with more intensive treatment. Thus, patient preferences and values regarding treatments should play a major role in determining glycemic targets. Finally, the type of treatment that is required to achieve a specific target significantly impacts the likelihood of benefits and harms. Lifestyle modification is unlikely to result in harm. Metformin is also considered safe but may cause adverse gastrointestinal effects. An HbA 1c target lower than 7% may be reasonable for some patients with the use of this relatively safe medication. In contrast, insulin is associated with the highest risk of hypoglycemia 68 compared with other agents and confers about a 2-fold increased risk compared with sulfonylurea treatment. 63 Furthermore, insulin requires significant self-management capacity, and insulin therapy can frequently result in treatment errors. Thus, for some older patients who are unable to achieve their glycemic target with oral medications, the appropriate response may be to discuss the trade-offs involved in the decision to start insulin rather than reflexively intensify treatment. Other harms or adverse effects of therapy (Table 2 ) may also influence the decision to modulate the glycemic target. Therefore, based on RCTs and observational data, the harms associated with an HbA 1c target lower than 7.5% or higher than 9% are likely to outweigh the benefits for the majority of older adults. A large part of the evidence is based on observational studies with a risk of bias. Some of the evidence is based primarily on expert opinion (level C evidence).
Minimize Polypharmacy
Most patients' HbA 1c levels increase over time, and patients and their clinicians must decide whether to intensify therapy. Decisions to deintensify therapy must also be made when HbA 1c levels decline, the risk of harms increases, or the treatment burden becomes unacceptable to the patient (Table 3) .
Evidence for Diminishing Benefits With Polypharmacy
The first glucose-lowering medication, which is often started at higher HbA 1c levels compared with the levels when the second agent is started, decreases HbA 1c more than subsequent medications. Starting a second or third medication for glycemic control leads to smaller reductions in HbA 1c than starting that same medication as monotherapy. 69, 70 For example, a meta-analysis of trials examining the efficacy of oral glucose-lowering agents showed that for patients with baseline HbA 1c levels between 9.0% to 9.9%, oral agents decreased HbA 1c levels by 1.0%. For patients with baseline HbA 1c levels between 8.0% to 8.9%, oral agents decreased HbA 1c levels by only 0.6%; for patients with baseline HbA 1c levels between 6.0% to 6.9%, the average reduction was only 0.2%. 71 
Evidence for Increasing Harms With Polypharmacy
Multiple studies have shown that polypharmacy increases the number of adverse drug events, 72, 73 including severe hypoglycemia, 63, 74 drug-drug interactions, 75, 76 interactions with coexisting comorbidities, 77 and patient costs. 78 In addition, the higher the number of medications, the less likely the patient will remain adherent with the treatment regimen. 79, 80 Furthermore, diabetes treatments such as insulin and dietary restrictions impose burdens on patients with the consequence of decreased quality of life. 81 Based on these data, in older patients with type 2 diabetes, increasingly intensive efforts to lower glucose levels with the use of multiple medications tend to be associated with diminishing benefits and greater risks of harm. Although there is consistent evidence with regards to harms of polypharmacy, the balance of benefits and harms has not been evaluated in RCTs (level C evidence). Table 3 outlines circumstances when clinicians and patients should consider decreasing or stopping medications and how this can be done.
Discussion
Currently, older patients with diabetes and their clinicians must make decisions on how best to manage hyperglycemia with limited evidence. These decisions need to balance what is known about the benefits and harms of treatment but require extrapolating evidence from younger, healthier patients, resulting in substantial uncertainty. Furthermore, different patients place different values on possible outcomes of treatment. Because these trade-offs are complex and because the strategies to lower glucose levels require active engagement of patients with respect to adherence and lifestyle behaviors, there is an imperative to involve the patients in the process. A shared-decision-making process, in the course of which a patient and his/her clinician discuss and weigh the likely outcomes from different treatment options, can take into account the best available evidence, as well as the patient's values and preferences about treatment. 82, 83 The Figure presents an approach to help older patients and their clinicians individualize glycemic treatment decisions. The process of shared decision making starts with establishment of a strong partnership that serves as the basis for exchange of information. 84 Estimation of life expectancy can help determine whether it is possible for a patient to realize the potential long-term benefits of intensive glycemic control. Several important patient-level factors such as the need for insulin, duration of diabetes, and cognitive im- Step 1a: Estimate macrovascular benefits of intensive glycemic control
Preponderance of evidence suggests intensive glycemic control does not decrease cardiovascular events in older adults
Step
Step 2 Estimate harms of intensive glycemic control
Step 3 Individualize glycemic target (HbA 1c range, 7.5%-9%)
Step 4 Minimize polypharmacy
Step HbA 1c < target Decrease or discontinue highest-risk medication (usually the last medication started [see Mrs K is 82 years old and functionally independent and has had a history of type 2 diabetes for the past 7 years. She has been treated with 1000 mg of metformin twice daily without any adverse effects. She also has dyslipidemia, hypertension, and chronic kidney disease. Her HbA 1c value is 7.6%, her creatinine level is 1.5 mg/dL (to convert creatinine from mg/dL to μmol/L, multiply by 88.4) with an estimated glomerular filtration rate (eGFR) of 40 mL/min/1.73 m 2 .
Estimate Benefits
The lag time to benefit from intensive glycemic control is likely in the order of 10 years. Short-term benefits of reducing HbA 1c to lower than 7.5% for her are unclear.
Estimate Harms
Addition of oral medications or insulin may increase treatment burden, risk of adverse effects (including hypoglycemia), treatment errors, and increase costs of care.
Individualize HbA 1c Target
Current HbA 1c is reasonable, pending a discussion with the patient regarding preferences for treatment. Focus should be on reducing risk of cardiovascular events with blood pressure and lipid control.
Minimize Polypharmacy
Although metformin is contraindicated in women with a creatinine level of 1.5 mg/dL or higher, the risk of lactic acidosis appears to be very low. 85 Metformin monotherapy can be safely continued with more frequent monitoring of renal function (every 3-6 months depending on rate of decline) and at a reduced dose (500 mg twice daily). 85 Because metformin has an excellent safety record and is not associated with either weight gain or hypoglycemia, it remains the first choice agent for treatment of type 2 diabetes.
Case 2
Mrs B is 85 years old and has type 2 diabetes of 10 years' duration. She is functionally dependent, living in a nursing home, with moderate dementia (Mini-Mental State Examination score, 18), depression, hypertension, dyslipidemia, osteoporosis, history of falls, and urinary incontinence. She is taking metformin 500 mg twice daily, glipizide 10 mg twice daily, sitagliptin 100 mg once daily, and pioglitazone 15 mg once daily. Her HbA 1c value is 7.1%. She has not had any known hypoglycemia.
Estimate Benefits
Benefits of intensive glycemic control are unclear in functionally dependent patients with limited life expectancy like Mrs B.
Estimate Harms
Mrs B takes multiple medications and is at increased risk of falls and adverse effects from medications.
Individualize HbA 1c Target
Her HbA 1c target can be relaxed given her multiple comorbidities to reduce polypharmacy. It is reasonable for her HbA 1c value to be in the 8% range. The discussion with patient and caregivers should focus on lack of benefits for intensive glycemic control and potential risk of harm with 4 agents.
Minimize Polypharmacy
To minimize Mrs B's medication burden, she could stop taking pioglitazone because it is associated with weight gain, lower extremity edema, risk of heart failure, and osteoporosis in women. Sitagliptin could also be stopped given its relatively low efficacy and high cost.
Metformin and glipizide could be continued. Routine monitoring of blood glucose is not recommended for patients taking oral medications; however, she is at risk of hypoglycemia, and intermittent monitoring may be helpful to assess for hypoglycemic events. Her glipizide dose can be reduced or stopped if there is any hypoglycemia.
Case 3
Mr C is 78 years old and has had type 2 diabetes for the past 10 years. He has nephropathy (eGFR ≈ 30 mL/min/1.73 m 2 ), mild retinopathy, and peripheral neuropathy. He has established coronary artery disease and had coronary artery bypass graft 6 years ago. He has osteoarthritis and limited mobility. For his diabetes, he takes glimepiride 4 mg twice a day and linagliptin 5 mg once daily. His HbA 1c value is 8.1%.
Estimate Benefits
The discussion with the patient should focus on trade-offs between escalating therapy (eg, with insulin) vs continuing current regimen (with glimepiride and linagliptin). Given that his HbA 1c value is higher than 8%, intensifying treatment may result in modest reductions in cardiovascular events and microvascular events. These benefits are likely to emerge after 10 years of treatment.
Estimate Harms
On the other hand, intensifying therapy may require insulin and can be associated with a high treatment burden.
The discussion with the patient should also focus on his risk of hypoglycemia. The patient has several risk factors for hypoglycemia, including chronic kidney disease and presence of established microvascular complications. He should be aware of hypoglycemia symptoms, be able to monitor blood glucose, and be asked to report any symptoms or low blood glucose results to the office.
Individualize HbA 1c Target
Current HbA 1c level is reasonable, pending a discussion with the patient regarding preferences for treatment. Rather than initiating insulin and increasing his risk of hypoglycemia, it is reasonable to continue current oral medications and accept a higher HbA 1c target.
Minimize Polypharmacy
Stopping medications is likely to result in an HbA 1c increase that is well above his glycemic target.
Case 4
Mrs D is a 79-year-old widow, functionally independent, living alone. She has hypertension, dyslipidemia, chronic obstructive pulmonary disease, chronic kidney disease, osteoarthritis, and osteoporosis. She has had type 2 diabetes for the past 40 years. She currently takes insulin glargine, 42 U at bedtime, and insulin aspart, 5 U with breakfast, 7 U with lunch, and 9 U with dinner. She takes additional insulin aspart based on a blood glucose scale with each meal. She has had symptomatic hypoglycemia over the past week, with blood glucose levels down to 50 mg/dL, without a clear pattern. Her blood glucose values range from 51 to 345 mg/dL, but she does not keep an organized log and admits that she sometimes forgets to take her insulin. Her HbA 1c level is 7.8%.
Estimate Benefits
Mrs D has long-standing diabetes that is unlikely to be safely managed without the use of insulin. However, benefits of intensive glycemic control in her case are unclear and unlikely to be realized during her lifetime.
Estimate Harms
Harms of insulin therapy include severe hypoglycemia, especially among older patients with complex health problems like Mrs D. Complex insulin regimen also increases treatment burden. Treatment errors are frequent and her cognitive status needs to be assessed to determine her capacity for self-management.
Individualize HbA 1c Target
Type 2 diabetes control may be too tight, and her insulin regimen overly complex, given the harms and burdens of treatment. Focus should shift to prevention of symptomatic hyperglycemia and keeping her HbA 1c values in the 8% range may be reasonable, while avoiding hypoglycemia.
Minimize Polypharmacy
Her insulin regimen needs to be simplified to reduce the risk for errors. A first step may be to reduce her glargine dose and prescribe a fixed dose of aspart with each meal. Depending on her schedule of meals, premixed insulin injections twice daily may be another option.
Conclusions
Although there are major gaps in the evidence base on how best to care for older adults with diabetes, 4 evidence-informed steps can help clinicians and patients make individualized treatment decisions. Patient-centered decisions start with a strong partnership between the clinician and the patient. The first and second steps include assessments of potential benefits and harms of intensive glycemic control. Estimation of life expectancy can be useful to determine whether long-term benefits of intensive glycemic control are possible. The need for insulin (or other type of therapy), duration of diabetes, and cognitive impairment can be used to determine the likelihood of harms associated with treatment. In the third step, patient preferences should play a major role in determining the appropriate glycemic target. Fourth, polypharmacy should be minimized. If a glycemic target cannot be easily achieved, the most appropriate course may be to modify the glycemic target rather than intensify treatment. 
